Hematology Week 2: Failure of Bone Marrow Flashcards
Bone Marrow failure causes
Can be congenital or acquired

Constitutional Aplastic Anemia examples
4 listed
- Fanconi Anemia
- Shwachman-Diamon Syndrome
- Dyskeratosis congenita
- Diamond-Blackfan Syndrome (red-cell aplasia)
Acquired Bone Marrow Failure examples
2 listed
Idiopathic aplastic anemia
Paroxysmal nocturnal hemoglobinuria (PNH)
BM failure vs Aplastic Anemia
not equal terms
aplastic anemia is a form of BM failure

Criteria for Aplastic anemia
- Cytopenia
- Hypocellular Marrow

Cellularity to age
age 80 = 20% cellularity
Causes of Acquired Aplastic Anemia
6 listed
Idiopathic - majority of cases

Idiopathic aplastic anemia Etiology
- Immune-mediated process underlying idiopathic aplastic anemia pathogenesis
- oligoclonally expanded cytotoxic T cells induce apoptosis of hematopoietic progenitors (Tregs significantly reduced, increased Thelp cells) indicative of antigen driven process
- Suggestive HLA class-I drive autoimmunity in Aplastic Anemia

Idiopathic Aplastic Anemia clinical Features
4 listed
- Thrombocytopenia is a prominent feature
- Small PNH clone detected
- High TPO level
- Benefit from immunosuppressive therapy
Pancytopenia

- very empty
- not enough RBCs
- Not enough Platelets
- Not enough Neutrophils

Management of Aplastic Anemia
5 main
- need to rule out folate and B12 deficiency
- gastric bypass can resect where vitamins are absorbed

Treatment of Idiopathic Aplastic Anemia
HSCT is curative

Prognosis of Idiopathic Aplastic Anemia
50-80% 5 year survival

If a sibling is not available for HSCT then Idiopathic Aplastic Anemia is treated with?
Immunosuppressive Therapy
- Horse ATG

Horse ATG
in conjunction with prednisone and cyclosporine

Idiopathic Aplastic Anemia Horse ATG or

Idiopathic Aplastic Anemia can evolve into
MDS/AML
Idiopathic Aplastic Anemia Supportive Care
very open to infections and fungal infections so prophylactic bacterial and fungal medications

Drugs of Drug-induced Aplastic Anemia

Infection-induced Aplastic Anemia
4 listed

Parvovirus B19 is commonly associated with
- Megaloblastic anemia
- 5% will have aplastic anemia
Case study

erythroblasts with nuclear inclusions of Parvovirus B19

Parvovirus B19 stain


Parvovirus B19 can cause?

PNH AKA
Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH Etiology
4 listed
- Acquired disorder of HSC
- a defect in the phosphatidylinositol glycan complementation class A (PIGA) gene which leads to a defect in GPI synthesis
- GPI are membrane anchors for other proteins such as enzymes, receptors, complement regulators CD55 and CD59 and adhesion molecules
- When CD55 and CD59 are missing, complement activation will lead to MAC formation, thus intravascular hemolysis

GPI AKA
Glycophosphatidylinositol
PNH Treated with?
- Eculizumab
- the MAC will be blocked however C3 will accumulate and the RBCs will be preyed on by macrophages because of complement deposition
- before treatment Coombs test is negative but after treatment Coombs test is positive

PNH Progressivity

PNH Clinical Presentation
4 listed

Diagnosis of PNH

Ham Test
No longer used

PNH diagnosis test of choice
cells that dont have CD157 and FLAER are PNH clones because they dont not have the anchor proteins

RBC PNH Test

% of patients with PNH will progress to?
30% to Aplastic Anemia
PNH Unique Relationship to Aplastic Anemia

Only _________ Aplastic Anemia can develop a PNH clone
Acquired
Management of PNH
2 listed
eculizumab (targe on complement protein C5)

Constitutional BM failure Syndromes
Fanconi Anemia
Shwachman-Diamond Syndrome
Dyskeratosis Congenita
Diamond-Blackfan Syndrome (red cell aplasia)
More types

Fanconi Anemia
5 main

Fanconi Anemia common manifestation
Failure of BM production
Fanconi Anemia Age of onset
can be young but some patients remain undiagnosed until adulthood
Fanconi Anemia Test
Increased Chromosomal Breakage when induced with chemicals
Fanconi Anemia Genetics
- at least 16 FA gene mutations have been discovered
- loss of function in DNA repair
FA HSC
- Impaired HSC pool
- progressive Attrition of HSCs

FA Diagnostic Test
Chromosomal breakage study
FA physical Manifestations
- short stature
- abnormal internal organ formation (kidney, urinary, heart, eyes, ears, etc..)
- malformed thumbs and or forearms

Dyskeratosis Congenita Etiology
shortened telomeres

Dyskeratosis Congenita Hereditary patterns
very diverse can be
- X-linked
- autosomal recessive
- autosomal dominant
Dyskeratosis Congenita Clinical Features

Dyskeratosis Congenita % developing malignancies
Dyskeratosis Congenita BM failure
occurs by 20 years in 80% of patients
Dyskeratosis Congenita mucocutaneous abnormalities
often present in early childhood before 10 years
Diagnosis of Dyskeratosis Congenita
- very difficult to diagnose
- no single test can definitively diagnose
Mucocutaneous changes and family history become very important

Shwachman-Diamond Syndrome

Shwachman-Diamond Syndrome Age of onset
Infancy with exocrine pancreatic insufficiency and progressive bone marrow failure
Shwachman-Diamond Syndrome Clinical presentations
- Exocrine pancreatic insufficiency
- progressive bone marrow failure
- Neutropenia is the most common presentation
- BM failure progresses to complete in 25% of patients and to MDS/AML in 5%-33% of patients
Shwachman-Diamond Syndrome Genetics
Shwachman-Bodian-Diamond Syndrome gene (SBDS) on chromosome 7
Shwachman-Diamond Syndrome Pathogenesis
- unknown
- mutations may affect RNA processing or ribosomes
Diamond-Blackfan Anemia Genetics
- Mutations of Ribosomal genes (RPS19, RPL5, RPL11, RPL35A, and others)
Diamond-Blackfan Anemia Clinical Presentations
- Thumb malformation
- craniofacial abnormalities
- Macrocytic anemia
- Paucity of erythroid precursors in the BM (pure red cell aplasia)
Diamond-Blackfan Anemia Increased risks of
Developing acute leukemia
Diamond-Blackfan Anemia pictures
erythroid lineage is missing

Next Generation Sequencing

Fanconi Anemia Clinical Management
5 listed
- HSCT - curative option
- Colony stimulating factors for support
- androgens - mechanism is unclear
- monitor for solid organ malignancies
- Gene therapy TNF-Alpha inhibitors are currently being investigated

Dyskeratosis Congenita Clinical Management
- HSCT Curative option
- Androgen therapy - modulates TERT gene expression and slows telomerase attrition

Shwachman-Diamond Syndrome Clinical Management
- Hematologic abnormalities no treated unless severe
- Transfusion as necessary
- G-CSF/prophylactic antibiotics for severe neutropenia
- HSCT for severe pancytopenia or progression to MDS/AML
- Monitor CBC q3-6 months and BM 1-3 years
- pancreatic enzyme replacement

Diamond-Blackfan Anemia Clinical Management
- Corticosteroids
- Transfusion/iron chelation
- HSCT
- Remission is possible (reason is unknown)

BM Failure Summary

BM Failure Summary

BM Failure Summary
